KalVista Pharmaceuticals, Inc.
KALV
$13.31
$0.100.76%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 71.71M | 81.07M | 91.00M | 93.47M | 86.17M |
| Gross Profit | -71.71M | -81.07M | -91.00M | -93.47M | -86.17M |
| SG&A Expenses | 116.29M | 100.36M | 80.64M | 62.09M | 54.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 188.00M | 181.42M | 171.63M | 155.57M | 140.45M |
| Operating Income | -188.00M | -181.42M | -171.63M | -155.57M | -140.45M |
| Income Before Tax | -180.05M | -171.62M | -156.39M | -141.77M | -126.64M |
| Income Tax Expenses | 3.39M | 4.25M | -- | -- | -- |
| Earnings from Continuing Operations | -183.45 | -175.87 | -156.39 | -141.77 | -126.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -183.45M | -175.87M | -156.39M | -141.77M | -126.64M |
| EBIT | -188.00M | -181.42M | -171.63M | -155.57M | -140.45M |
| EBITDA | -187.06M | -180.52M | -170.76M | -154.72M | -139.63M |
| EPS Basic | -3.69 | -3.73 | -3.64 | -3.54 | -3.40 |
| Normalized Basic EPS | -2.28 | -2.30 | -2.29 | -2.23 | -2.15 |
| EPS Diluted | -3.69 | -3.73 | -3.64 | -3.54 | -3.40 |
| Normalized Diluted EPS | -2.28 | -2.30 | -2.29 | -2.23 | -2.15 |
| Average Basic Shares Outstanding | 198.61M | 189.16M | 171.24M | 159.11M | 147.29M |
| Average Diluted Shares Outstanding | 198.61M | 189.16M | 171.24M | 159.11M | 147.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |